People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
Ketamine, the controlled drug best known as a horse tranquilizer or party supplement, has in the last four years become a ...
Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...
Dr Adrian Wang, who runs his own clinic at Gleneagles Medical Centre, has administered Spravato to 17 patients, so far, and the therapy has failed only twice for him, he said. “One lady stopped ...
Dr Adrian Wang, who runs his own clinic at Gleneagles Medical Centre, said he has administered Spravato to 17 patients so far, and the therapy has failed only twice. “One lady stopped because ...
Spravato is a first-of-its-kind medication ... Ketamine has been used by clinics across the U.S. to treat depression, anxiety and post-traumatic stress disorder (PTSD). Over 100 out-of-state ...